Recent studies have centered on the convergence of glucagon-like peptide-1|GIP|GCGR agonist therapies and DA neurotransmission. While GLP activators are commonly employed for treating type 2 diabetes mellitus, their potential consequences on reinforcement circuits, specifically influenced by dopamine networks, are gaining substantial interest. This